Myelofibrosis future or investigational therapies: Difference between revisions
No edit summary |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Myelofibrosis}} | {{Myelofibrosis}} | ||
{{CMG}} | {{CMG}}{{AE}}{{Sab}} | ||
==Overview== | ==Overview== | ||
Future and investigational therapies involve immunomodulatory drugs, histone deacetylase inhibitors, newer generation drugs of already existing medications and drugs targeting pathways other than the JAK/STAT. The goal is to limit the need for allogeneic stem cell transplantation. | Future and investigational [[Therapy|therapies]] involve [[Immunomodulator|immunomodulatory]] drugs, [[histone deacetylase]] [[Enzyme inhibitor|inhibitors]], newer generation drugs of already existing [[Medication|medications]] and drugs targeting pathways other than the [[JAK-STAT signaling pathway|JAK/STAT]]. The goal is to limit the need for [[allogeneic stem cell transplantation]]. | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
*Future or investigational therapies involve: | *Future or investigational [[Therapy|therapies]] involve: | ||
:*Immunomodulatory drugs<ref name="pmid30324817">{{cite journal |vauthors=Zimran E, Keyzner A, Iancu-Rubin C, Hoffman R, Kremyanskaya M |title=Novel treatments to tackle myelofibrosis |journal=Expert Rev Hematol |volume=11 |issue=11 |pages=889–902 |date=November 2018 |pmid=30324817 |doi=10.1080/17474086.2018.1536538 |url=}}</ref> | :*[[Immunomodulator|Immunomodulatory]] drugs<ref name="pmid30324817">{{cite journal |vauthors=Zimran E, Keyzner A, Iancu-Rubin C, Hoffman R, Kremyanskaya M |title=Novel treatments to tackle myelofibrosis |journal=Expert Rev Hematol |volume=11 |issue=11 |pages=889–902 |date=November 2018 |pmid=30324817 |doi=10.1080/17474086.2018.1536538 |url=}}</ref> | ||
:*Histone | :*[[Histone deacetylase]] [[Enzyme inhibitor|inhibitors]] | ||
:*Second-generation Janus kinase 1/2 inhibitors | :*Second-generation [[Janus kinase 1]]/[[Janus kinase 2|2]] [[Enzyme inhibitor|inhibitors]] | ||
==References== | ==References== | ||
Latest revision as of 21:28, 18 December 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis future or investigational therapies |
|
Myelofibrosis future or investigational therapies in the news |
|
Risk calculators and risk factors for Myelofibrosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[2]
Overview
Future and investigational therapies involve immunomodulatory drugs, histone deacetylase inhibitors, newer generation drugs of already existing medications and drugs targeting pathways other than the JAK/STAT. The goal is to limit the need for allogeneic stem cell transplantation.
Future or Investigational Therapies
- Future or investigational therapies involve:
- Immunomodulatory drugs[1]
- Histone deacetylase inhibitors
- Second-generation Janus kinase 1/2 inhibitors
References
- ↑ Zimran E, Keyzner A, Iancu-Rubin C, Hoffman R, Kremyanskaya M (November 2018). "Novel treatments to tackle myelofibrosis". Expert Rev Hematol. 11 (11): 889–902. doi:10.1080/17474086.2018.1536538. PMID 30324817.